Dillon & Associates Inc. Sells 8,400 Shares of Johnson & Johnson (NYSE:JNJ)
Dillon & Associates Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 18.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,018 shares of the company’s stock after selling 8,400 shares during the period. Johnson & Johnson makes up approximately 1.6% of Dillon & Associates Inc.’s investment portfolio, making the stock its 26th largest holding. Dillon & Associates Inc.’s holdings in Johnson & Johnson were worth $4,849,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in JNJ. Tamarack Advisers LP acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $18,035,000. Orser Capital Management LLC increased its position in shares of Johnson & Johnson by 44.2% in the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock valued at $272,000 after acquiring an additional 575 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $31,000. Arkfeld Wealth Strategies L.L.C. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $536,000. Finally, SeaCrest Wealth Management LLC increased its position in shares of Johnson & Johnson by 5.8% in the fourth quarter. SeaCrest Wealth Management LLC now owns 49,644 shares of the company’s stock valued at $7,241,000 after acquiring an additional 2,718 shares during the last quarter. 67.66% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson stock opened at $144.37 on Friday. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock’s 50 day moving average is $146.81 and its 200-day moving average is $142.30. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $386.52 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 3.19 and a beta of 0.71.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be given a $1.01 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Friday, May 22nd. This represents a $4.04 annualized dividend and a dividend yield of 2.80%. Johnson & Johnson’s dividend payout ratio is presently 43.78%.
JNJ has been the topic of a number of recent research reports. UBS Group downgraded Johnson & Johnson from a “buy” rating to a “neutral” rating and lowered their target price for the company from $163.00 to $160.00 in a research report on Tuesday, April 28th. Citigroup lifted their target price on Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Argus reissued a “buy” rating and set a $155.00 price target (down previously from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Raymond James boosted their price target on Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Finally, SVB Leerink lowered their price target on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $163.47.
In other news, Director William D. Perez bought 500 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were bought at an average price of $127.69 per share, with a total value of $63,845.00. Following the completion of the transaction, the director now owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: How does inflation affect different investments?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.